Accelerate Diagnostics

Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The company's revolutionary ID/AST platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. In addition to the Accelerate ID/AST System development pipeline, the company also owns and licenses its proprietary OptiChem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
Company Growth (employees)
Type
Public
HQ
Tucson, US
Founded
2004
Size (employees)
193 (est)
Accelerate Diagnostics was founded in 2004 and is headquartered in Tucson, US

Accelerate Diagnostics Office Locations

Accelerate Diagnostics has offices in Tucson and Castelldefels
Tucson, US (HQ)
3950 S Country Club Rd
Castelldefels, ES
1 Carrer Esteve Terradas

Accelerate Diagnostics Financials and Metrics

Accelerate Diagnostics Financials

Accelerate Diagnostics's revenue was reported to be $246 k in FY, 2016
USD

Net income (Q2, 2017)

(30.7 m)

Market capitalization (13-Nov-2017)

1.1 b

Cash (30-Jun-2017)

62.6 m
Accelerate Diagnostics's current market capitalization is $1.1 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

48.3 k122 k147 k246 k

Revenue growth, %

153%20%67%

R&D expense

28.2 m

Operating expense total

28.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

13 k14 k92 k163 k

R&D expense

4.6 m6.4 m6.5 m7.4 m

Operating expense total

8.2 m9.6 m11.3 m15.3 m

EBIT

(8.2 m)(9.6 m)(11.2 m)(15.2 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

30 m53.6 m120.6 m19.2 m

Accounts Receivable

24.4 k78 k77 k155.7 m

Current Assets

42.1 m67.1 m134.2 m78.4 m

PP&E

1 m2.5 m5 m4.3 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

65.2 m57.9 m47.4 m35.2 k25.2 m72 m37.5 m28.7 m9.9 m62.6 m

Inventories

4.4 m5.7 m

Current Assets

79.7 m72.7 m59.7 m49.4 k40.9 m120.3 m105.4 m91.7 m70.3 m143.3 m

PP&E

1.9 m2.3 m3.5 m3.8 k3.7 m5.2 m5 m4.8 m3.9 m4.8 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.4 m)(3.4 m)(45.5 m)(66.4 m)

Depreciation and Amortization

42.7 k43 k1.8 m2.4 m

Accounts Receivable

(13 k)(13 k)1 k43 k

Inventories

10.3 k10 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(8.2 m)(22.2 m)(8.9 m)(21.1 m)(11.2 m)(15.1 m)(50.2 m)(14.2 m)

Depreciation and Amortization

150 k592 k326 k5 k468 k545 k8 k3 k

Accounts Receivable

106.2 k40 k40 k(65 k)92 k143742 k169 k159 k551 k

Inventories

4.4 m
Y, 2017

Financial Leverage

1 x
Show all financial metrics

Accelerate Diagnostics Market Value History

Accelerate Diagnostics's Web-traffic and Trends

Accelerate Diagnostics Online and Social Media Presence

Accelerate Diagnostics Company Life and Culture

You may also be interested in